{'52WeekChange': 1.1758242,
 'SandP52WeekChange': 0.0644362,
 'address1': '955 Chesterbrook Boulevard',
 'address2': 'Suite 110',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 2,
 'askSize': 1800,
 'averageDailyVolume10Day': 5188837,
 'averageVolume': 3225701,
 'averageVolume10days': 5188837,
 'beta': 2.740056,
 'beta3Year': None,
 'bid': 1.97,
 'bidSize': 1100,
 'bookValue': 0.291,
 'category': None,
 'circulatingSupply': None,
 'city': 'Chesterbrook',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 2,
 'dayLow': 1.86,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -7.27,
 'enterpriseToRevenue': 6206.656,
 'enterpriseValue': 192406336,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 1.6194286,
 'fiftyTwoWeekHigh': 2.2,
 'fiftyTwoWeekLow': 0.46,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 105788695,
 'forwardEps': -0.21,
 'forwardPE': -9.428572,
 'fromCurrency': None,
 'fullTimeEmployees': 24,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.030639999,
 'heldPercentInstitutions': 0.20526,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/trevena.com',
 'longBusinessSummary': 'Trevena, Inc., a biopharmaceutical company, focuses '
                        'on the development and commercialization of novel '
                        'medicines for patients affected by central nervous '
                        'system disorders. Its product candidates include '
                        'Oliceridine injection, a G protein biased mu-opioid '
                        'receptor (MOR) ligand that has completed Phase III '
                        'clinical trials for the management of '
                        'moderate-to-severe acute pain where intravenous '
                        'administration is warranted; TRV250, a G protein '
                        'biased delta-opioid receptor agonist that has '
                        'completed Phase I clinical study for the treatment of '
                        'acute migraine; TRV734, a small molecule G protein '
                        'biased ligand of the MOR that has completed Phase I '
                        'clinical study for the treatment of '
                        'moderate-to-severe acute and chronic pain; TRV027 for '
                        'the treatment of acute heart failure; and TRV045, a '
                        'novel S1P modulator for managing chronic pain. The '
                        'company has a collaboration with Imperial College '
                        'London to evaluate Trv027 in Covid-19 patients. '
                        'Trevena, Inc. was founded in 2007 and is '
                        'headquartered in Chesterbrook, Pennsylvania.',
 'longName': 'Trevena, Inc.',
 'market': 'us_market',
 'marketCap': 212218384,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_41390678',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -25427000,
 'nextFiscalYearEnd': 1640908800,
 'open': 1.93,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '610-354-8840',
 'previousClose': 1.93,
 'priceHint': 4,
 'priceToBook': 6.8041234,
 'priceToSalesTrailing12Months': 6845.7544,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 2,
 'regularMarketDayLow': 1.86,
 'regularMarketOpen': 1.93,
 'regularMarketPreviousClose': 1.93,
 'regularMarketPrice': 1.93,
 'regularMarketVolume': 2142059,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 107181000,
 'sharesPercentSharesOut': 0.0653,
 'sharesShort': 6999613,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 4694331,
 'shortName': 'Trevena, Inc.',
 'shortPercentOfFloat': 0.066,
 'shortRatio': 2.2,
 'startDate': None,
 'state': 'PA',
 'strikePrice': None,
 'symbol': 'TRVN',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.272,
 'twoHundredDayAverage': 1.0226762,
 'volume': 2142059,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.trevena.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '19087'}